Top 10 Building Product Stocks To Watch Right Now

Small cap green stocks Eco Depot Inc (OTCMKTS: ECDP), Eco Building Products Inc (OTCMKTS: ECOB) and Profire Energy, Inc (OTCBB: PFIE) has been getting some extra attention lately in various investment newsletters thanks to paid promotions or investor relation campaigns. Of course, there is nothing wrong with properly disclosed promotions and investor relations campaigns, but small cap green stocks tend to be extra volatile when compared with other stocks. So how in greenbacks will these three small cap green stocks produce for investors? Here is a quick reality check:

Eco Depot Inc (OTCMKTS: ECDP) Has the Swiss Army Knife of Water Purifiers

Small cap Eco Depot Inc was formerly an "eco lighting" distributor under new management as the company is in the development stage of transitioning into a manufacturer and distributor of eco friendly consumer brand products. On Friday, Eco Depot Inc fell 6.06% to $0.0930 for a market cap of $4.54 million plus ECDP is up 210% over the past year and down 79.8% over the past five years according to Google Finance.

Top 10 Low Price Companies To Invest In 2015: Inovio Pharmaceuticals Inc (INO)

Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.

Inovio�� Solution

The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.

The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.

Cancer Synthetic Vaccines

The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.

Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.

Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).

In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.

Infectious Disease Synthetic Vaccines

In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.

The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.

Animal Health/Veterinary

VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.

The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.

Advisors' Opinion:

• [By MONEYMORNING]

  Inovio Zooms: We recommended biotech Inovio Inc. (NYSE: INO) at 71 cents a share back on Feb. 1, 2013, and have re-recommended it a number of times since. With their 15.2% gain yesterday, the shares are now at $3.71, up 414% from where we first told you about them - and we believe there's more to come. In fact, we'll be bringing you an interesting update on this company very soon. Inovio is one of 24 recommendations that have doubled or better since we launched Private Briefing back in August 2011.

• [By George Budwell]

  Inovio Pharmaceuticals (NYSEMKT: INO  ) develops DNA-based vaccines and delivers them using a proprietary electroporation technique. Shares of Inovio have been a roller coaster all year long, and have certainly been the playground of day traders. Last week, Inovio shares lost more than 10% of their value on heavy volume, suggesting the stock may continue to experience downward pressure. This rapid move downward is surprising because the company recently signed a licensing deal with Roche (NASDAQOTH: RHHBY  ) to commercialize Inovio's multi-antigen DNA immunotherapies for prostate cancer and hepatitis B. As part of the deal, Inovio received $10 million upfront, and milestone payments could go as high as $412 million.

Top 10 Building Product Stocks To Watch Right Now: iShares Short-Term National AMT-Free Muni Bond ETF (SUB)

iShares 2016 AMT-Free Muni Term ETF, formerly iShares S&P Short Term National AMT-Free Municipal Bond Fund (the Fund), is an exchange-traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the S&P Short Term National AMT-Free Municipal Bond Index (the Index). The Index measures the performance of the short-term investment-grade segment of the United States municipal bond market. The Fund invests in a representative sample of the securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors. Advisors' Opinion:

• [By Todd Rosenbluth]

  Two others are iShares Short-Term National AMT-Free Municipal Bond ETF (SUB) and Market Vectors Short Municipal Index ETF (SMB).

  The Market Vectors fund, not surprisingly, has more A bond exposure and less AA exposure than the iShares fund. However, both have lower average durations than iShares National AMT-Free Muni Bond and thus might appeal to investors concerned about the impact of higher rates.

Top 10 Building Product Stocks To Watch Right Now: International Tower Hill Mines Ltd (THM)

International Tower Hill Mines Ltd. (ITH) is an exploration-stage company. The Company is engaged in the business of acquiring, exploring and evaluating mineral properties, and either joint venturing or developing these properties further or disposing of them when the evaluation is completed. As of December 31, 2011, the Company controlled a 100% interest in its Livengood project in Alaska, the United States. The Livengood property is located approximately 115 kilometers northwest of Fairbanks, Alaska in the Tolovana Mining District within the Tintina Gold Belt. The property is approximately 145 square kilometers and consists of fee land leased from the Alaska Mental Health Trust. The project area is centered on Money Knob. Advisors' Opinion:

• [By Holly LaFon]

  He increased his holdings in gold companies in the fourth quarter accordingly. Gold stocks he found attractive in the fourth quarter are: Novagold Resources (NG), Randgold Resources (GOLD), Iamgold Corp. (IAG), Barrick Gold Corp. (ABX), Agnico Eagle (AEM) and International Tower Hill (THM).

• [By Anthony Mirhaydari]

  For now, I continue to recommend investors maintain a cautious stance, focusing on the buying interest coming into safe-haven assets like U.S. Treasury bond and precious metals while booking profits in biotech stocks that have been red hot this month. The leveraged Direxion 3x Treasury Bond Bull (TMF) is up nearly 7% in my Edge Letter Sample Portfolio since it was added on Jan. 10. I just sold Tower Hill Mines (THM) and Rosetta Genomics (ROSG) for gains of 46% and 18% respectively.

• [By Bryan Murphy]

  With no revenues, and therefore no profits, International Tower Hill Mines Ltd (NYSEMKT:THM) shouldn't qualify as "investment worthy" in any way, shape, or form. Indeed, the near-100% loss that THM shares have suffered since early 2011 might scare off even the gutsiest of traders. Yet, there's something undeniably bullish about this stock right now.

Top 10 Building Product Stocks To Watch Right Now: First Trust Specialty Finance and Financial Opportunities Fund (FGB)

First Trust Speciality Finance and Financial Opportunities Fund, formerly First Trust/Gallatin Specialty Finance and Financial Opportunities Fund, is a non-diversified, closed-end fund that seeks a high level of current income. The Fund�� secondary objective is to seek total return. The Fund will seek to achieve its investment objectives by investing at least 80% of its managed assets in a portfolio of securities of specialty finance and other financial companies that offer opportunities for income and capital appreciation. The Fund will invest at least 25% of its total assets in securities of companies within industries in the financial sector. First Trust Advisors L.P. (First Trust Advisors) is the Fund's investment adviser.

Specialty finance companies provide capital or financing to businesses and consumers within specified market segments. Specialty finance companies often engage in asset-based and other forms of non-traditional financing activities. The Fund intends to invest primarily in business development company�� (BDC) shares, which are trading in the secondary market on a United States securities exchange but may, in certain circumstances, invest in an initial public offering of BDC shares or invest in certain debt instruments issued by BDCs. The Fund is not limited with respect to the specific types of real estate investment trusts (REITs), in which it invests and intends to invest primarily in REIT shares, which are trading in the secondary market on a United States securities exchange but may, in certain circumstances, invest in an initial public offering of REIT shares or invest in certain debt instruments issued by REITs.

The Fund may invest in commercial mortgage-related securities issued by corporations. These are securities that represent an interest in, or are secured by, mortgage loans secured by commercial property, such as industrial and warehouse properties, office buildings, retail space and shopping malls, multi-family properties and cooperati! ve apartments, hotels and motels, nursing homes, hospitals, and senior living centers. Other mortgage-related securities, in which the Fund may invest include mortgage pass-through securities, collateralized mortgage obligations (CMOs), mortgage dollar rolls, CMO residuals (other than residual interests in real estate mortgage investment conduits), stripped mortgage-backed securities (SMBSs) and other securities that directly or indirectly represent a participation in, or are secured by and payable from, mortgage loans on real property. The Fund may invest in other types of asset-backed securities that are offered in the marketplace. Other asset-backed securities may be collateralized by the fees earned by service providers.

The principal industry groups of financial companies include banks, savings institutions, brokerage firms, investment management companies, insurance companies, holding companies of the foregoing, and companies that provide related services to such companies. Banks and savings institutions provide services to customers such as demand, savings and time deposit accounts and a variety of lending and related services. Brokerage firms provide services to customers in connection with the purchase and sale of securities.

Advisors' Opinion:

• [By Shaji Mathew]

  JPMorgan also raised the price estimate of First Gulf Bank, (FGB) its top pick among banks in the Middle East and North Africa, to 18 dirhams from 13.50 dirhams. The overweight recommendation was maintained. The stock has risen 25 percent this year to 14.55 dirhams last week.

Top 10 Building Product Stocks To Watch Right Now: Carnival Plc ADS (CUK)

Carnival plc operates as a cruise company. It operates in North America Cruise Brands, EAA Cruise Brands, and Tour and Other segments. The company offers cruises under the brand names of Carnival Cruise Lines, Holland America Line, Princess Cruises, and Seabourn in North America; and AIDA Cruises, Costa Cruises, Cunard, Ibero Cruises, P&O Cruises (UK), and P&O Cruises (Australia) in Europe, Australia, and Asia. It also owns Holland America Princess Alaska Tours, a tour operator in Alaska and the Canadian Yukon, which owns and operates 12 hotels or lodges, 300 motor coaches, and 20 domed rail cars. The company sells its cruises through travel agents, including wholesalers, general sales agents, and tour operators. Carnival plc was founded in 1850 and is headquartered in London, the United Kingdom.

Advisors' Opinion:

• [By Eric Volkman]

  Carnival (NYSE: CCL  ) (NYSE: CUK  ) has launched an "enhancement program" that will total hundreds of millions of dollars. The investments will be directed at boosting the safety of its ships and include modifications that the company says will "enhance emergency power capabilities, introduce new fire safety technology, and improve the level of operating redundancies" throughout Carnival's 24-strong fleet.

Top 10 Building Product Stocks To Watch Right Now: Crumbs Bake Shop Inc (CRMB)

Crumbs Bake Shop, Inc., formerly 57th Street General Acquisition Corp., incorporated on October 29, 2009, is owner of Crumbs Holdings LLC (Crumbs), a neighborhood bakery and a retailer of cupcakes. As of November 1, 2011, Crumbs had 43 locations, including 29 locations in the New York Metro area, nine locations on the West Coast, three locations in Washington, D.C., one location in Virginia and one location in Chicago. The specialty of the house is cupcakes; however, the menu also includes a blend of baked goods. On May 5, 2011, the Company merged with Crumbs.

The Company offers a range of Signature and Taste size cupcakes. Signature cupcakes are ordered in increments of six. One can create its own individual six packs or choose a pre-selected assortment. Its Taste size cupcakes are offered by the dozen in pre-selected favorites assortments. There are more than 60 varieties of cupcakes baked fresh daily with a new cupcake of the week debuting each Monday.

Advisors' Opinion:

• [By Jack Kramer and Nick Martell]

  2. Crumbs Cupcake stock continues to drop
  Pour some sugar on me, baby, because the recent performance of cupcake-makin' chain Crumbs Bake Shop (NASDAQ: CRMB  ) hasn't tasted good for investors. The stock has fallen nearly 30% in the past month, dropped 13.4% in the last week, and dipped almost 2% Monday on growing doubts the company can even stay in business.

• [By John Kell and Tess Stynes var popups = dojo.query(".socialByline .popC"); p]

  Crumbs Bake Shop Inc.(CRMB) said interim Chief Executive Edward M. Slezak has been named permanently to post, while also announcing that its board has appointed Frederick G. Kraegel as chairman.

• [By Kyle Woodley]

  I love cupcakes. More specifically, I love Crumbs Bake Shop (CRMB) cupcakes. I absolutely do.

  That�� why it pains me to say that CRMB stock is dead money.

Top 10 Building Product Stocks To Watch Right Now: diaDexus, Inc. (DDXS)

diaDexus, Inc. (diaDexus), incorporated on November 27, 1995, is a medical diagnostics company. The Company is focused on the development and commercialization of in vitro diagnostic products addressing unmet needs in cardiovascular disease. diaDexus�� product, the PLAC Test, helps identify individuals suffering a heart attack or stroke, the #1 and #3 causes of death, respectively in the United States. The PLAC Test measures Lp-PLA2, which is a vascular-specific inflammatory marker implicated in the formation of rupture-prone plaque.

GlaxoSmithKline (GSK) has developed an Lp-PLA2 inhibitor (darapladib) and is testing the drug in two large, global, Phase III clinical trials involving over 27,000 patients to determine if inhibition of the enzyme reduces cardiovascular events. The PLAC Test is a blood test, available nationally through clinical reference, hospital, and advanced cardiovascular diagnostic laboratories.

Advisors' Opinion:

• [By Peter Graham]

  Small cap medical device or biotech related stocks Therapeutic Solutions International Inc (OTCMKTS: TSOI), diaDexus, Inc (OTCMKTS: DDXS) and Spherix Inc (NASDAQ: SPEX) have been getting some attention lately in various investment newsletters with the good news being that it appears none are the subject of paid promotions from stock promoters. So why are these three stocks all of a sudden getting some attention and what else do you need to know about them before you make a short or a long term bet on one? Here is a closer look at the whole picture and what you might be missing:

• [By Peter Graham]

  Small cap stocks Pulse Network Inc (OTCBB: TPNI), Sterling Consolidated Corp (OTCBB: STCC) and diaDexus, Inc (OTCMKTS: DDXS) have or could start to sizzle for investors. However, I should also mention that two of these stocks have been the subject of paid promotions while a third apparently has not been, and could be the real deal. With that in mind, here is a closer look along with a quick reality check about all three small caps to help you decide whether they are hot or not: